Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-936559 in Severe Sepsis
NCT02576457Phase 1Terminated
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2015
- Primary completion
- Mar 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in sepsis and septic shock comparing BMS-936559 with Placebo (2 arms). Primary endpoints: Safety of BMS-936559 at 3 months, Tolerability of BMS-936559 at 3 months and 1 more. Started Dec 2015; status: terminated.
02
Drugs
BMS-936559
03
Conditions
sepsisseptic shock
Beyond the preview
Go deeper on NCT02576457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02576457.